Clinical Trial Update: Open-Label Treatment Extension of Protocol MNTX 301 [Phase 3]

View source ↗

Summary

Open-label treatment extension of a Phase 3 study (MNTX 301) has completed, indicating final trial results or continuation beyond the core protocol.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Terminal Illness

Snippet

Sponsor: Bausch Health Americas, Inc. | Conditions: Terminal Illness | Phase 3 | Status: COMPLETED